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ABSTRACT 
 
Background: An increased incidence of acute group A ß-hemolytic Streptococcal 
(GABHS) pharyngitis has been reported anecdotally at the Welcare Hospital in Dubai.  
 
Aim: To describe the outcomes of patients with acute GABHS pharyngitis who received 
standard therapy at the Welcare hospital emergency unit in Dubai.  
 
Objectives  
To determine the time elapsed before patients experience a clinically significant 
reduction in pain.  
To describe the side-effect profile of standard treatment received for acute GABHS 
pharyngitis.  
 
Methods: This is a cross-sectional study design. Consecutive sampling of 123 patients 
was done from December, 2013 to March, 2014. A questionnaire was used to record 
demographic data and severity of GABHS before patients received standard treatment. 
The Visual Analogue Scale (VAS) was used to measure pain severity at baseline and 
during follow-up. Adults diagnosed with GABHS pharyngitis who received 
dexamethasone as part of standard treatment offered were included.  
 
Results: Clinical pain relief, which was suggested as a VAS score of 4, was achieved by 
5.7% of the patients at 12 hours. At 24 hours, 55.3% of the patients reported a VAS 
score of 4. The mean VAS score of the patients at this time was 4.12. A total of 99.2% of 
the patients reported a VAS score of 4 or lower at 36 and 48 hours. Paired t-test 
revealed statistically significant difference between the VAS scores at 12, 24, 36 and 48 
hours and baseline (p=0.000). This suggests that clinical pain relief was achieved by 
55.3% of the patients at 24 hours. At 48 hours, 21.1% of the patients reported a VAS 
score of 0. None of the patients reported any side effects associated with the one dose 
use of dexamethasone.  
 
Conclusion: The findings suggest that dexamethasone is safe and effective to use as 
adjuvant for management of pain associated with acute GABHS pharyngitis. Almost all 
patients experienced significant pain relief by 36 and 48 hours and no side-effects 
related to dexamethasone use were recorded. Further definitive randomised controlled 
trials are needed to establish these findings as evidence for practice. 
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I. INTRODUCTION  
 
Sore throat is among the commonest upper respiratory disorders reported in 2004 in 
Dubai with about 21, 244 cases of upper respiratory tract infections treated at primary 
health care centers the same year. (1) Upper respiratory tract infection rank among the 
top three most common diseases in the region with acute pharyngitis making up to 40% 
of this type of infection. (1,2) In the year 2004, there were 9, 746 cases of acute 
pharyngitis. (1) 
 
Sore throat or acute pharyngitis is a common condition and is caused by bacterial or 
viral infections. (2) The most common bacteria causing acute pharyngitis are the group 
A ß-hemolytic Streptococci (GABHS) e.g. Streptococcus pyogenes. (2) Symptoms and 
signs such as pain, fever, absence of cough, anterior cervical lymph nodes and tonsillar 
exudates are used to diagnose acute GABHS pharyngitis. (2) The presence of three or all 
of these criteria have a positive predictive value of 40 to 60%, while absence of three or 
four of the criteria have a negative predictive value of 80%. (3) When these criteria are 
implemented in actual settings, the specificity and sensitivity of both measures are 
approximately 75%. (3) 
 
The symptom of pain is generated when the pharynx and the lymphatic tissues that 
surround the pharynx become inflamed. (4) To reduce the pain, antibiotic treatment is 
given for bacterial infection, shortening the duration of the symptoms by as much as 2.7 
days. (4) However, pain relief from antibiotic treatment is only moderate. The 
indiscriminate use of antibiotics is also discouraged in order to reduce the incidence of 
antibiotic resistance. (2) Supportive treatments such as oral analgesic, antipyretics or 
gargling of warm liquids may offer temporary pain relief. (4) In some patients suffering 
from severe pain, intramuscular (IM) or oral steroids are considered since these have 
been suggested to reduce inflammation and swelling faster than oral antibiotics. (4) 
Furthermore, randomised controlled trials (RCTs) suggested that patients suffering 
severe pain due to acute GABHS pharyngitis reported earlier pain relief with steroid 
therapy. (5,6,7,8) 
 
Considering that increasing numbers of patients are suffering from respiratory 
infections in Dubai, there is a need to provide quality health care to these patients to 
ensure that they are adequately relieved of their symptoms during treatment.  
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However, there remains a paucity of studies describing the onset of pain relief following 
IMI or oral 10 mg dexamethasone in the current clinical research literature. In addition 
studies documenting the side effects from this kind of therapy have also not been 
reported. This study seeks to describe how patients presenting with symptoms of 
confirmed GABHS acute pharyngitis to Welcare Hospital would respond to the standard 
treatment regimen of acute pharyngitis, which include the use of dexamethasone.  
 
II. LITERATURE REVIEW  
 
Dexamethasone is a corticosteroid that is used to relieve inflammation in patients. (9, 
10) The drug has many uses, which include relief of symptoms of pain in patients 
suffering from acute exudative pharyngitis. (10) The use of oral or intramuscular 
dexamethasone is shown to be effective in reducing pain levels in patients suffering 
from acute pharyngitis. (5) Onset of pain relief for patients receiving dexamethasone 
was 4 hours earlier as compared to those who were not administered with the 
corticosteroid. (5) Intramuscular injection of dexamethasone reduced pain levels faster 
than oral dexamethasone.(5) Wei et al. (5) further suggested that identification of the 
pathogen causing the acute pharyngitis would also play a role in the response of the 
patients to dexamethasone.  
 
The study of Wei et al. (5) had a relatively large sample size (n=118) and the use of a 
double-blind controlled trial design minimised researcher bias. (9) Determining the 
effectiveness of an intervention requires quality randomised controlled trials as this 
type of study design provides robust results as compared to other study designs. The 
use of a control group serves as a basis for comparison of effects from a treatment 
group. (11) Furthermore, the effect size of the treatment could be determined when 
there is a larger sample size and patients are randomised to treatments. (12) However, 
the study did not provide data on numbers needed to treat (NNT).  
 
A similar study among children ages 5 to 16 years old, however, showed a different 
result. Bulloch et al. (6) conducted a prospective, randomised, double blind, placebo-
controlled trial among 184 children with acute pharyngitis in an emergency department. 
A rapid streptococcal antigen detection test was used to group the children. A total of 85 
children tested positive while 99 children tested negative. Results showed that for 
children with group A beta-hemolytic streptococcal pharyngitis, the median time to 
experience relief from pain was 6 hours after oral dexamethasone. In the placebo group, 
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the median hours for clinically significant pain relief were 11.5 hours. Complete pain 
relief in both subgroups was however, similar at 36 hours. In the antigen-negative 
group, the median hours for clinical significant pain relief in the dexamethasone group 
were 13 hours while in the placebo group, the median hours for pain relief was 9 hours. 
Complete pain relief was similar at approximately 48 hours, which suggests that oral 
dexamethasone did not reduce the time to achieve clinically significant pain relief. 
However, for children with GABHS acute pharyngitis, oral dexamethasone did reduce 
the time of onset of clinically significant pain relief when compared to the placebo 
group. A review of the study also shows that it was robust and of high quality as 
researchers and patients were both blinded to the treatments offered. This would lessen 
researcher bias during interpretation of results. (10, 12)   
 
Apart from the two RCTs mentioned above, two systematic reviews (7, 8) evaluated the 
effectiveness of steroids or corticosteroid in the treatment of acute GABHS pharyngitis. 
In the study by Wing et al. (7), corticosteroid treatment was examined for its 
effectiveness in relieving pain associated with acute GABHS pharyngitis. Findings 
revealed that when compared to placebo, corticosteroids provided a clinically 
meaningful 4.5 times reduction in pain relief. However, when follow-up was done at 24 
hours, pain reduction using the visual analogue scale was not significantly different 
when compared to the placebo group. An important aspect of this systematic review 
was the determination of short-term side effects of the corticosteroids when compared 
to the placebo group. Analysis revealed that side effects were similar in both groups. 
However Wing et al. (7) suggested that treatment should be individualised and the use 
of corticosteroids not administered as routine treatment. This suggestion might have 
resulted from the observation that the use of corticosteroids provided pain relief during 
the period immediately after administration. Pain reduction, however, was similar to the 
placebo group 24 hours after corticosteroids were administered.  
 
In another systematic review, (8) steroids were used as adjuvant therapy for patients 
suffering from acute pharyngitis. Findings suggested that dexamethasone provided pain 
relief 5.5 hours earlier when compared to other steroids such as prednisone or 
betamethasone. Findings of the review suggested that when a 10 mg IMI of 
dexamethasone was used as adjuvant to standard therapy, it led to rapid onset of pain 
relief for adults. In children, 10 mg of oral dexamethasone provided pain relief.  
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Systematic reviews (10) have been increasingly conducted in recent years to gather 
evidence on current medications or interventions for certain conditions. Quality 
systematic reviews allow health care practitioners to investigate whether an 
intervention is effective or not. The abovementioned two systematic reviews included 
only randomised controlled studies in their reviews. These studies suggest the 
effectiveness of dexamethasone as adjuvant treatment in relieving pain in patients 
receiving standard therapy for acute pharyngitis.  
 
One gap seen in the studies reviewed (13, 14, 1,5, 16, 17, 18) is the lack of 
documentation of side effects of one dose of dexamethasone. It would appear that the 
focus of these studies was only in determining the effectiveness of dexamethasone in 
relieving pain. Today, the practise of administering oral or intramuscular 
dexamethasone as adjuvant therapy for acute GABHS pharyngitis varies widely. (18) In 
the UK, the NICE guideline (19), has not yet recommended the use of oral or IM 
dexamethasone in treating acute GABHS pharyngitis. The guideline is focused on 
delaying or withholding antibiotic treatment to prevent the side effects associated with 
constant use of antibiotics. However, it is suggested that oral or IM dexamethasone 
could provide pain relief in the absence of antibiotics. (9)  
 
III. AIM AND OBJECTIVES: 
 
The aim of this study was to assess pain relief in the first 48 hours among patients with 
acute GABHS pharyngitis who received standard therapy at the Welcare hospital 
emergency unit, Dubai. 
 
The objectives of this study were as follows: 
1. Determine the number of hours elapsed before patients experience clinically 
significant reduction in pain.  
2. Describe the side-effect profile of standard treatment received for acute GABHS 
pharyngitis 
 
IV. METHODS 
4.1 Setting: 
This study was conducted in the emergency unit of the Welcare Hospital in Dubai. This 
unit receives 6000 to 7000 patients each month. Approximately 1500-2000 of these 
patients suffers from upper respiratory tract infections (URTI). A third of those with 
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URTI are diagnosed with acute pharyngitis. Dubai’s Welcare Hospital Emergency Unit 
currently has a standard treatment protocol for acute GABHS pharyngitis, which 
includes the administration of antibiotics (if patient is positive for GABHS) and the 
administration of intramuscular injection (IMI) or oral administration of 10 mg 
dexamethasone. 
 
4.2 Study Design:  
A descriptive cross sectional study design was utilised.  
 
4.3 Sample Selection Strategy: 
Patients were recruited through consecutive sampling. Inclusion criteria included the 
following: only adult patients who are at least 18 years old; who had no other health 
conditions except acute pharyngitis; who received usual care, which included the once 
off administration of dexamethasone as part of pain management; and who were 
residents of Dubai. All patients included had a rapid streptococcal antigen detection test 
performed.  
 
4.4 Sample Size:  
The study was descriptive and with the assistance of a statistician it was decided that 
all consecutive patients attending the emergency unit for treatment of acute GABHS 
pharyngitis over a period of three months were recruited for the study. The final 
sample size was dependent on the availability of patients who met the inclusion criteria 
at the time of study. This provided baseline information on the effects of dexamethasone 
in reducing pain in patients presenting with symptoms of acute GABHS pharyngitis. 
While consecutive sampling might not be representative of the whole population of 
patients in Dubai diagnosed with acute GABHS, the sample population would provide 
information on how patients receiving dexamethasone respond to this adjuvant 
treatment.  
 
4.5 Instrument: 
A checklist to obtain basic demographic data, the presence and severity of acute 
pharyngitis was used. In addition, the Visual Analogue Scale (VAS) (Appendix A) was 
used to measure the severity of pain of the patients at baseline and regular intervals 
after receiving standard usual treatment offered for acute GABHS pharyngitis. The scale 
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runs from zero to ten where zero represents no pain and ten the worst pain the patient 
could experience. 
 
Pain perception is known to be difficult to measure (20) but the validity of the VAS tool 
in assessing pain is well established.(20,21) Three areas of validity such as criterion 
validity, content and construct validity have been established. Content validity would 
refer to the extent to which the tool can measure pain and nothing else. (21) Construct 
validity, on the other hand, would refer to the extent to which the measuring tool is 
consistent with other tools in measuring pain. (21) Finally, criterion validity would 
require that the measuring tool could predict an observable phenomenon. (20,21) The 
sensitivity and specificity of VAS have also been established. A number of studies (13, 
14, 15, 16, 17, 18) have established the specificity and validity of these tools in 
measuring pain.  
 
4.6. Data collection: 
Once patients had signed informed consent to participate in the study, measurement of 
pain was done with the use of the Visual Analogue Scale (VAS). A score of “10” indicated 
maximum pain experienced and a score of “0” indicated no pain. The patients’ level of 
pain relief was recorded at baseline and at 12, 24, 36 and 48 hours follow up. The 
researcher and field workers followed-up the patients by telephone. The participants 
were also asked to report any side effects related to use of dexamethasone such as 
headache, increased sweating, dizziness, nausea or stomach pain, muscle weakness and 
sleep problems after standard treatment was administered. (13, 14) Patients would 
have received 10 mg of dexamethasone intramuscularly as part of their usual standard 
care at Dubai hospital emergency centre.  
 
4.7 Ethical Considerations: 
The researcher explained the aims and objectives of the study to each patient who was 
administered with dexamethasone. Once the patient consented to be followed-up in the 
next 48 hours, the patient was asked to sign informed consent. Participants were also 
assured that their identities were protected and they would remain anonymous 
throughout the study.  Once data became available, electronic data were password 
protected while hard copies were kept in locked file cabinets. The Institutional Review 
Board and the Ethics Department of the University of Stellenbosch approved the study. 
Password protected data would be kept for future reference at the completion of the 
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study. Findings will be disseminated at the Welcare Hospital and other academic 
research forum. 
 
4.7 Data analysis 
Statistical Package for Social Sciences (SPSS) was used to analyse data. The mean score 
at the onset of clinical pain relief was recorded. This was done by subtracting the VAS 
score at baseline from the VAS score at 12, 24, 36 and 48 hours follow-up. The 
researcher conducted the follow-up through telephonic discussion with the patient. The 
participants were asked to report any side effects experienced after treatment had been 
administered. The Dependent t-test for paired samples was used to detect significant 
changes of mean VAS pain scores from baseline to 12, 24, 36 and 48 hours follow-up. 
Side-effects were not statistically treated since none of the participants reported any 
side-effects during follow-up.   
 
V. RESULTS  
 
A total of 123 patients were consecutively sampled during this period. More females 
(n=68) were recruited than males (n=55). The mean age of the patients was 31.3 ± 9.6 
years.  Almost a third, 29.3% (n=36) of the patients were positive in the rapid 
streptococcal antigen test while 70.7% (n=87) reported negative for the test. Majority of 
participants, 62.6% (n=77) consented to receive antibiotics while 37.4% did not receive 
antibiotics (n=46).   
 
Baseline: Visual Analogue scores for throat pain at baseline is shown in table 1. 
The VAS score at this time ranged from 6 to 10 with a mean score of 8.3. The vast 
majority of participants (74.8%) scored their pain 8 to 9. 
 
Table 1. Patients’ visual analogue scale (VAS) score at baseline 
 
  Frequency Percent  Cumulative 
Percent 
Valid 6 6 4.9  4.9 
  7 11 8.9  13.8 
  8 57 46.3  60.2 
  9 35 28.5  88.6 
  10 14 11.4  100.0 
  Total 123 100.0    
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12 hours after baseline: Patient VAS scores after 12 hours ranged from 4-8. Only 5.7% 
(7) reported a pain score of 4 after 12 hours following the administration of 
dexamethasone. Results also showed that the mean VAS score had decreased to 6.11 
from a mean VAS score of 8.3 at baseline. More than 52% (64) reported a pain score of 
6. Table 2 presents the frequency of patients with VAS scores of 4 to 8:  
 
Table 2.  Patients’ visual analogue scale (VAS) scores after 12 hours 
 Frequency Percent  Cumulative 
Percent 
Valid 4 7 5.7  5.7 
  5 19 15.4  21.1 
  6 64 52.0  73.2 
  7 20 16.3  89.4 
  8 13 10.6  100.0 
  Total 123 100.0    
 
After 24 hours: The mean VAS score of the patients was 4.12. VAS scores ranged from 1 
to 7. More than half 55.3% (68) of the patients reported a VAS score of 4. Results reveal 
that majority of the patients experienced clinical relief at 24 hours as shown in table 3.  
 
Table 3. Patients’ visual analogue scale (VAS) scores after 24 hours 
 Frequency Percent  Cumulative 
Percent 
Valid 1 1 .8  .8 
  2 14 11.4  12.2 
  3 5 4.1  16.3 
  4 68 55.3  71.5 
  5 21 17.1  88.6 
  6 12 9.8  98.4 
  7 2 1.6  100.0 
  Total 123 100.0    
 
36 hours after: Mean VAS scores of the patients at 36 hours was 2.16. Almost 70% of 
the patients reported a pain score of 2 as shown in table 4:  
 
Table 4.  Patients’ visual analogue scale (VAS) scores after 36 hours 
 
 Frequency Percent  Cumulative 
Percent 
Valid 1 17 13.8  13.8 
  2 83 67.5  81.3 
  3 12 9.8  91.1 
 12 
  4 8 6.5  97.6 
  5 3 2.4  100.0 
  Total 123 100.0    
 
After 48 hours: The mean VAS scores was only 1.24. Twenty-six of the patients 
reported a pain score of 0 and only 1 patient reported a pain score of 5. The majority or 
75.6% either reported a pain score of 1 or 2 as reflected in table 5.  
 
Table 5.  Patients’ visual analogue scale (VAS) scores after 48 hours 
 Frequency Percent  Cumulative 
Percent 
Valid 0 26 21.1  21.1 
  1 51 41.5  62.6 
  2 42 34.1  96.7 
  4 3 2.4  99.2 
  5 1 .8  100.0 
  Total 123 100.0    
 
Clinical pain relief was determined by subtracting the VAS scores at 12, 24, 6 and 48 
hours from the baseline VAS scores. The table 6 below presents the Mean VAS scores at 
baseline, 12, 24, 36 and 48 hours and clinical pain relief:  
 
Table 6. Clinical Pain Relief 
Time Mean Vas Scores Clinical Pain Relief 
(baseline- VAS score) 
Baseline 8.33  
12 hours 6.11 8.33-6.11= 2.22 
24 hours 4.12 8.33-4.12= 4.21 
36 hours 2.16 8.33-2.16= 6.17 
48 hours 1.24 8.33-1.24= 7.09 
 
As presented in the table above, clinical pain relief at 12 hours was 2.22 and 4.21 at 24 
hours. This increased to 6.17 at 36 hours and 7.09 at 48 hours.  
 
Results of the paired sample t-test revealed a statistically significant difference 
(p=0.000) between the means of the VAS scores at baseline and at 12 hours. The same 
results are also seen between the means of the VAS scores at baseline and at 24 hours 
(p=0.000). Statistically significant differences in the mean scores at baseline and at 36 
and 48 hours were also observed (p=0.000).  
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Side-effects: None of the patients reported any adverse effects associated with 
dexamethasone during the 48-hour period of follow up.  
 
VI. DISCUSSION 
Pain management is essential to promote positive health outcomes amongst patients. 
(21) Physiological effects of unmanaged pain include increased heart rate, a 
compromised immune system and increased risk of stress and depression. (21) All these 
could delay recovery of patients suffering from pain related to a health condition. 
Results of this study show that administration of dexamethasone resulted in a reduction 
of pain scores as shown by the visual analogue scale. While there were statistically 
significant differences between the mean scores at baseline and during the follow-ups at 
12, 24, 36 and 48 hours, clinical pain relief shown by a score of 4 or less was achieved at 
24 hours in the majority of patients. Miller (22) suggests that a VAS score of 4 is 
considered as a critical threshold in determining whether patients have benefitted from 
a therapy.  
 
Miller (22) explains that patients who report a VAS score of 4 tends to show 
improvements compared to patients who report pain scores higher than 4. Results show 
that patients report a mean score of 4.12 at 24 hours. This suggests that pain severity 
reduced significantly with time elapsed from baseline. However, findings also show that 
at 12 hours, only 5.7% of the patients reported a VAS score of 4. At 24 hours, more than 
half or 55% of the patients already reported a pain score of 4. Almost all (97.6%) of the 
patients reported a VAS score of 4 and lower at 36 hours. This shows that almost all of 
the patients clinically benefitted from dexamethasone at 36 hours. At 48 hours, 99.2% of 
the patients reported a VAS score of 4 and lower. Importantly, 21.1% of the patients 
reported a VAS score of 0 or complete pain relief at 48 hours.  
 
Since this study is descriptive, it was impossible to determine if similar findings are 
observed when patients receive only antibiotics to manage acute GABHS pharyngitis. An 
earlier study (4) suggests that pain relief from GABHS pharyngitis following antibiotic 
medication is achieved at 2.7 days using VAS tool. However, investigators of this study 
failed to report the proportion of patients who reported a VAS score of 4 during the 
follow-up period. This could have provided information on whether clinical pain relief 
was achieved earlier. When compared to the findings of the present study, mean VAS 
score of 4 was achieved at 24 hours. At this time, more than half of the patients already 
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reported pain scores of 4, which has been suggested to lead to improvements in health 
outcomes. (22) At 48 hours, almost all of the patients already reported a VAS score of 4 
or lower, suggesting that clinical pain relief is achieved at 48 hours. (4)  
 
The findings of the present study are also supported by that of Wei et al. (5) who 
showed that clinical pain relief was achieved 4 hours earlier with IM dexamethasone 
compared to placebo only. This suggests that use of dexamethasone in pain 
management is feasible since earlier pain relief is achieved. Results of this study show 
that pain relief is attained within the first 24 hours of administration of the drug. 
Although comparisons were not made between patients who received dexamethasone 
and those who only received antibiotics or supportive treatment, results of the present 
study suggests that dexamethasone could be used for pain management.  
 
In the present study, none of the patients reported any side effects associated with 
steroid use during the follow-up period. Concerns (6,7,8) have been raised on the 
possible side effects of dexamethasone. Side effects of dexamethasone are similar to 
other steroids, which could include cushingnoid effects. (23) However, these become 
more evident with prolonged use of steroids.  (23) It is still unclear whether the risk of 
developing these side effects would be similar if a patient only receives the drug once as 
adjuvant therapy for pain management of acute pharyngitis.  
 
Findings of this study also highlight the importance of comparing when clinical pain 
relief is achieved between patients who received only antibiotics against those who 
received dexamethasone at the Welcare Hospital in Dubai. This would show which type 
of treatment could lead to earlier clinical pain relief. Although only a small proportion 
(29%), of patients tested positive for GABHS, more than twice the number of patients 
was prescribed antibiotics. This suggests the need for further physician and patient 
education on the uses and side effects of antibiotics, particularly where patients have 
tested negative for the rapid streptococcal antigen detection test . The findings suggest 
that administration of dexamethasone as part of standard care could successfully 
manage pain in patients suffering from acute GABHS pharyngitis. Furthermore, none of 
the patients who consented to be followed-up reported any side effects associated with 
dexamethasone.  
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VII: LIMITATIONS OF STUDY 
 
Findings should be taken with caution since this study was descriptive and did not 
recruit patients randomly. The investigator only recorded when clinical pain relief is 
achieved following the use of dexamethasone.  It is unclear if dexamethasone 
contributed to this pain relief since this study did not use a control group to compare 
findings. Another limitation of this study includes lack of comparison of VAS scores of 
patients who received dexamethasone against those who received antibiotics or 
supportive treatment only. Findings are only limited to the sampled population and 
could not be generalised to a larger and more heterogeneous population. Despite these 
limitations, the study suggests that the one dose of dexamethasone could be a safe 
alternative in pain management of patients with acute pharyngitis. It is also noteworthy 
that perception of pain is highly variable (24) with some having higher tolerance for 
pain while the rest may show a higher sensitivity to pain. Hence, the use of mean scores 
in the visual analogue scale might not truly reflect individual patient’s experience of 
clinical pain relief. Although a VAS score of 4 (22) has been reported to lead to better 
health outcomes and improvements, it is possible that even if patients report a pain 
score of 4, they might not experience better health outcomes.  
 
Despite the lack of generalisability, other health care settings might replicate similar 
findings upon administration of dexamethasone to manage pain in patients with acute 
GABHS pharyngitis. Importantly, the absence of reported side effects might be 
encouraging since a major concern regarding the use of dexamethasone is related to its 
reported side effects. Finally, it is recommended that a randomized controlled trial (RCT 
of dexamethasone versus placebo, sub-analyzed by antibiotic versus no antibiotic group 
should be conducted in order to establish the efficacy of dexamethasone.  
 
VIII. CONCLUSION  
 
The use of dexamethasone as adjuvant treatment in GABHS pharyngitis is safe and 
associated with rapid and clinically significant pain relief as early as within 24 hour after 
dexamethasone administration. In view of the limitations of this study, better- designed 
randomized controlled trials are needed to validate these findings.  
 
 
 16 
IX. REFERENCES: 
 
1. National Statistics Report 2004. Dubai: National Statistics Office; 2004.  
 
2. Melio F & Holmes D. Upper respiratory tract infections. In: Rosen P, Barkin R 
editors. Emergency medicine: concepts and clinical practice. 4th edn. St. Louis, 
MO: Mosby; 1998; 529-1553.  
 
3. Mintz M. Disorders of the respiratory tract: common challenges in primary care. 
New Jersey: Humana Press; 2006.  
 
4. Shores C. Infections and disorders of the neck and upper airway. In: Tintinalli J, 
Kelen G, Stapczynski J, editors. Emergency medicine: a comprehensive study 
guide. 6th edn. New York: McGraw-Hill Co; 2004; 1494-1501.  
 
5. Wei J, Kasperbauer J, Weaver A, Boggust A. Efficacy of single-dose as adjuvant 
therapy for acute pharyngitis. Laryngoscope. 2002;112: 87 -93.  
 
6. Bulloch B, Kabani A & Tenebein M. Oral dexamethasone for the treatment of pain 
in children with acute pharyngitis: a randomised, double-blind, placebo-
controlled trial. Ann Fam Med. 2003; 41(5): 601-608.  
 
7. Wing A, Villa-Roel C, Yeh B, et al. Effectiveness of corticosteroid treatment in 
acute pharyngitis: a systematic review of the literature. Acad Emerg Med. 2010: 
17(5): 476-483.  
 
8. Korb K, Scherer M, Jean-François, C. Steroids as adjuvant therapy for acute 
pharyngitis in ambulatory patients: a systematic review. Ann Fam Med. 2010: 
8(1): 58-63. 
  
9. Greenhalgh T. How to read a paper: the basics of evidence-based medicine. West 
Sussex, UK: John Wiley and Sons; 2010.  
 
10. Cooper R, Hofman J, Barlet J, et al. Principles of appropriate antibiotic use for 
acute pharyngitis in adults. Ann Intern Med. 2001;134:509-517.  
 
11. Hek G, Judd M, Moule P. Making sense of research (4th ed.). London: Sage 
Publications; 2011.  
 
12. Solomon P, Cavanaugh M, Daine, J. Randomised controlled trials: design and 
implementation for community-based psychosocial interventions. Oxford: 
Oxford University Press; 2009.  
 
13. Kiderman A, Yaphe, J, Bregman J, et al. Adjuvant prednisone therapy in 
pharyngitis: a randomised controlled trial for general practice. Br J Gen Pract. 
2005; 55(512): 218-221.  
 
14. Tesar A, Yanturali S, Topacoglu H, et al. Clinical efficacy of dexamethasone for 
acute exudative pharyngitis. J Emerg Med. 2008; 35(4): 363-367.  
 
15. Marvez-Valis E, Ernst A, Gray, J, Johnson W. The role of betamethasone in the 
treatment of acute exudative pharyngitis. Acad Emerg Med. 1998; 5(6): 567-572.  
 
 17 
16. Niland M, Bonsu B, Nuss K, Goodman D. A pilot study of 1 versus 3 days of 
dexamethasone as add-on therapy in children with streptococcal pharyngitis. 
Pediatr Infect Dis J. 2006; 25(6): 477-481. .  
 
17. Olympia R, Khine H, Avner J. Effectiveness of oral dexamethasone in the 
treatment of moderate to severe pharyngitis in children. Arch Pediatr Adolesc 
Med. 2005; 159(3): 278-282.  
 
18. Centor R, Allison J, Cohen S. Pharyngitis management: defining the controversy. J 
Gen Intern Med. 2007; 22(1): 127-130.  
 
19. National Institute for Clinical Excellence (NICE). Respiratory tract infections-
antibiotic prescribing. London: NICE; 2008. 
 
20. Kaplan E, Gooch W, Notario G, Craft JC. Macrolide therapy of group A 
streptococcal pharyngitis: 10 days of macrolide therapy (Clarithromycin) is 
more effective in streptococcal eradication than 5 days (Azithromycin). Clin 
Infect Dis. 2001;32:1798-1802.  
 
21. McMain, L. Principles of acute pain management. J Periop Pract. 2008;18:472-
478.  
 
22. Miller, G. Studying the difference between ‘statistical’ and ‘clinically meaningful’. 
Pain Medicine News. 2010; 8(9).  
 
23. Macintyre, P. & Schug, S. Acute pain management: A practical guide. 
Philadelphia, PA: Elsevier Limited; 2007.  
 
24. Kelly, A. The minimum clinically significant difference in visual analogue scale 
pain score does not differ with severity of pain. Emerg Med J. 2001; 18(3): 205-
207.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 18 
Appendix A. Visual Analogue Scale 
 
 
Instruction:  
 
The researcher will present the patient with the visual analogue score card below. The 
patient will be asked to point to a line between the faces to indicate how much pain they 
are currently feeling. A score of zero means ‘no pain’ while a 10 means ‘the most severe 
pain’.  
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Appendix C. Informed Consent 
 
 
